Quantitative structure-activity relationship study of antitubercular fluoroquinolones

Molecular Diversity

Volumn 15, Issue 2, 2011, Pages 417-426

  Minovski, Nikola ^a   Vračko, Marjan ^a   Šolmajer, Tom ^a  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

Author keywords

CP ANN; DNA gyrase; Fluoroquinolones; QSAR; Tuberculosist

Indexed keywords

QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOLOGICAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ALGORITHM; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; STATISTICAL MODEL;

ALGORITHMS; ANTITUBERCULAR AGENTS; DRUG DESIGN; FLUOROQUINOLONES; HUMANS; MODELS, STATISTICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80051553414     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-010-9238-5     Document Type: Article

References (44)

1. Kayukova LA, Praliev KD (2000) Main directions in the search for new antituberculous drugs. Pharm Chem J 34:11-18. doi:10.1007/BF02524551
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis estimated incidence, prevalence, and mortality by country. JAMA 282:677-686 (Pubitemid 29384157)
3. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003) Tuberculosis. Lancet 362:887-889. doi:10.1016/S0140-6736 (03) 14333-4
4. Janin YL (2007) Antituberculosis drugs: ten years of research. Bioorg Med Chem 15:2479-2513. doi:10.1016/j.bmc.2007.01.030 (Pubitemid 46367698)
5. Derouin F (2001) Anti-toxoplasmosis drugs. Curr Opin Invest Drugs 2:1368-1374 (Pubitemid 32994385)
6. Drlica K, Zhao X (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61:377-392 (Pubitemid 28090230)
7. Owens RC Jr, Ambrose PG (2000) Clinical use of the fluoroquinolones. Med Clin North Am 84:1447-1469
8. Hooper DC (2001) Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32:S9-S15 (Pubitemid 32506740)
9. Hooper DC (2001) Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7:337-341 (Pubitemid 32374357)
10. Ruiz J (2003) Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51:1109-1117. doi:10.1093/jac/dkg222 (Pubitemid 36622067)
11. Anquetin G, Greiner J, Vierling P (2005) Quinolone-based drugs against Toxoplasma gondii and Plasmodium spp. Curr Drug Targ: Infect Disord 5:227-245 (Pubitemid 41448369)
12. Block JH, Beale JM (eds) (2004) Whilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. Lippincott Williams & Wilkins, Philadelphia, pp 247-252
13. Maxwell A (1997) DNA gyrase as a drug target. Trends Microbiol 5:102-109 (Pubitemid 27139470)
14. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369-413 (Pubitemid 32662215)
15. Peng H, Marians KJ (1993) Escherichia-coli topoisomerase-ivpurification, characterization, subunit structure, and subunit interactions. J Biol Chem 268:24481-24490 (Pubitemid 23335445)
16. Reece RJ, Maxwell A (1991) DNA gyrase-structure and function. Crit Rev Biochem Mol 26:335-375
17. Levine C, Hiasa H, Marians KJ (1998) DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta 1400:29-43 (Pubitemid 28475094)
18. Oblak M, Kotnik M, Solmajer T (2007) Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 14:2033-2047 (Pubitemid 47578161)
19. Owners RC, Ambrose PG (2005) Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41:S144-S157 (Pubitemid 40962485)
20. Domagala JM (1994) Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimic Chemother 33:685-706 (Pubitemid 24149805)
21. NIAID-Division of AIDS, HIV/OI/TB Therapeutics Database. http://chemdb2.niaid.nih.gov
22. Talete srl, DRAGON for Windows (Software for Molecular Descriptor Calculations), version 5.4, 2006. http://www.talette.mi.it
23. Katritzky AR, Lobanov VS, Karelson M (1994) CODESSA, Reference Manual, Gainsville
24. Katritzky AR, Lobanov VS, Karelson M (1995) CODESSA, Training Manual, Gainsville
25. Minovski N (2009) DragCOD v1.0, laboratory for chemometrics. National Institute of Chemistry, Ljubljana
26. Zupan J, Gasteiger J (1999) Neural networks in chemistry and drug design. Wiley-VCH, Weinheim, 380pp
27. Vracko M (2005) Kohonen artificial neural network and counter propagation neural network in molecular structure-toxicity studies. Curr Comp-Aid Drug Des 1:73-78
28. Vracko M, Bandelj V, Barbieri P, Benfenati E, Chaudhry Q, Cronin M, Devillers J, Gallegos A, Gini G, Gramatica P, Helma C, Mazzatorta P, Neagu D, Netzeva T, Pavan M, Patlewicz G, Randic M, Tsakovska I, Worth A (2006) Validation of counter propagation neural network models for predictive toxicology according to the OECD principles: a case study. SAR QSAR Environ Res 17:265-284. doi:10.1080/10659360600787650 (Pubitemid 44034663)
29. Simon V, Gasteiger J, Zupan J (1993) A combined application of two different neural network types for prediction of chemical reactivity. J Am Chem Soc 115:9148-9159
30. Leonard JT, Roy K (2006) On selection of training and test sets for the development of predictive QSAR models. QSAR Comb Sci 25:235-251. doi:10.1002/qsar.200510161
31. Valkova I, Vračko M, Basak SC (2004) Modeling of structuremutagenicity relationships: counter propagation neural network approach using calculated structural descriptors. Anal Chim Acta 509:179-186. doi:10.1016/j.aca.2003.12.035 (Pubitemid 38340718)
32. Kotnik M, Oblak M, Humljan J, Gobec S, Urleb U, Solmajer T (2004) Quantitative structure-activity relationships of Streptococcus pneumoniae MurD transition state analogue inhibitors. QSAR Comb Sci 23:399-405. doi:10.1002/qsar.200430875 (Pubitemid 39490401)
33. Zupan J, Novic M, Gasteiger J (1995) Neural networks with counter propagation learning strategy used for modeling. Chemometr Intell Lab Systems 27:175-187
34. Novic M (2008) Artificial neural networks. In: Livingstone DS (ed) Methods and protocols. Humana Press, Totowa, pp 45-60
35. Mitscher LA (2005) Bacterial topolsomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev 105:559-592. doi:10. 1021/cr030101q (Pubitemid 40351634)
36. Jacobs MR (2004) Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr Pharm Des 10:3213-3220 (Pubitemid 39276610)
37. Mitscher LA, Ma ZK (2003) Structure-activity relationships of quinolones In: Ronald AR, Low DE (eds) Fluoroquinolone antibiotics. Birkhaeuser, Basel, pp 11-48
38. Ledoussal B, Almstead J-IK, Gray JL, Hu EX, Roychoudhury S (2003) Discovery, structure-activity relationships and unique properties of non-fluorinated quinolones (NFQs). Curr Med Chem: Agents 2:13-25. doi:10.2174/1568012033354531
39. Peterson LR (2001) Quinolone molecular structure-activity relationships: What we have learned about improving antimicrobial activity. Clin Infect Dis 33:S180-S186 (Pubitemid 32835789)
40. Topliss JG, Edwards RP (1979) Chance factors in studies of quantitative structure-activity-relationships. J Med Chem 22:1238-1244 (Pubitemid 10237430)
41. Smith JT (1984) Mutational resistance to 4-quinolone antibacterial agents. Eur J Clin Microbiol 3:347-350 (Pubitemid 14034599)
42. Topliss JG (1983) In: Topliss JG (ed) Quantitative structure-activity relationships of drugs. Academic Press, New York, pp 497-504
43. Zupan J (2003) Neural networks. In: Gasteiger J (ed) Handbook of cheminformatics. Wiley-VCH, Weinheim, pp 1167-1215
44. Vračko M, Mills D, Basak SC (2004) Structure-mutagenicity modelling using counter propagation neural networks. Environ Toxicol Pharmacol 16:25-36. doi:10.1016/j.etap. 2003.09.004 (Pubitemid 38314892)